FDA Grants Frontline Atezolizumab Priority Review for NSCLC

May 7, 2018 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The sBLA is a based on findings from the phase III IMpower150 trial, in which the atezolizumab regimen demonstrated a median progression-free survival (PFS) of 8.3 months … (leggi tutto)